Arovella Therapeutics (ALA) H2 2024 earnings summary

Executive summary

• Revenue from ordinary activities fell 98.8% to $17,000 for the year ended 30 June 2024, while net loss after tax improved by 14.1% to $(8,746,035) compared to the prior year.

• Net assets increased to $11,228,047 from $3,780,091, with cash reserves rising to $12,714,407, supported by $14.7 million in new equity raised.

• The company advanced its iNKT cell therapy platform, completed manufacturing scale-up for lead product ALA-101, and expects to initiate Phase 1 clinical trials in FY2025.

• Two new technology licenses were secured: a novel CAR targeting CLDN18.2 for solid tumors and an armouring technology (IL-12-TM) to enhance cell persistence and anti-tumor activity.

• The share price appreciated ~180% during the year, outperforming the broader biotechnology sector.

Financial highlights

• Total income for FY2024 was $2,090,857 (up from $1,484,681 in FY2023), mainly from R&D tax incentives and interest income.

• Cash and cash equivalents at year-end were $12,714,407, up from $5,175,338.

• Net tangible assets per share increased to 1.07 cents from 0.44 cents.

• No dividends were declared or paid.

• Market capitalization rose to $147.08 million from $42.50 million year-over-year.

Outlook and guidance

• IND submission for ALA-101 is expected in early Q1 CY2025, with Phase 1 clinical trial initiation anticipated in FY2025.

• Funds raised will support clinical development of ALA-101 and expansion of the iNKT cell therapy pipeline.